ACUTAAS Q2 FY27 Earnings Call: Guides ~30% Revenue Growth, Rs. 1,000 Cr CDMO Target Pulled Forward

ACUTAAS held its Q2 FY27 earnings call on October 27, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Broad-Based Beat with Margin Expansion Across the P&L

• Revenue of Rs.4,369 million, up 42.7% YoY — driven by strong pharmaceutical intermediates performance; the specialty chemicals business was muted during the quarter.
• Gross margin at 62.1%, up 637 bps YoY — gross profit of Rs.2,715 million (+59% YoY); management attributed expansion to both product mix and raw material prices but said it cannot bifurcate the two, and stated raw material prices did not soften in Q2 FY 2026-2027 ("definitely not the case").
• EBITDA of Rs.1,760 million, up 84.6% YoY — margin of 40.3%, up 914 bps YoY, attributed to gross margin expansion and operating leverage.
• PAT of Rs.1,231 million, up 71.4% YoY — PAT margin at 28.2%, an expansion of 472 bps YoY.
• H1 FY27 revenue of Rs.7,666 million, up 49.3% YoY — H1 EBITDA at Rs.2,890 million (+97.7% YoY, 37.7% margin, +922 bps); H1 PAT at Rs.1,981 million (+71% YoY, 25.8% margin).
• Net cash of ~Rs.3,009 million as on 30 September 2026 — though working capital rose to 115 days in Q2 FY 2026-2027 from 99 days in Q1 FY27, driven by higher debtor days.

FY27 Guidance Raised; CDMO Target Pulled Forward a Year

• FY 2026-2027 revenue growth guidance revised upward from 25% to ~30% — with EBITDA margin guidance raised to 38-40% from FY27; management confirmed the 38-40% band applies to FY27 and declined to extend it into FY28.
• Rs.1,000 crore CDMO revenue target now expected in FY27 — one year ahead of the original FY28 timeline set at the Q3 FY25 earnings call in January 2025; management called it "definitely achievable" based on customer visibility and contracts in place, with H2 FY27 order books already in place.
• New Rs.2,000 crore CDMO target by FY30 — the business is expected to double over the next three financial years from the Rs.1,000 crore level now expected in FY27; the second Rs.1,000 crore will be more diversified across multiple molecules and customers than the first.
• 8-10 products in the CDMO pipeline — 4 products validated a few quarters back are converting into orders, with 8-9 products expected to enter the revenue stream over the next 1-1.5 years; management reiterated Rs.50-100 crore revenue per molecule for non-blockbuster products (period unspecified).
• CDMO margins on the Rs.2,000 crore FY30 revenue — Abhishek Patel said EBITDA margins should be "largely in the same range" as current CDMO margins.
• A couple of pipeline products have billion-dollar potential — for the innovator customers; management declined to disclose product or therapeutic details, citing innovator-driven confidentiality.

Battery Ramp Underway; Korea Plant in Qualification Phase

• Q2 FY 2026-2027 was the first quarter of commercial battery chemicals revenue — commercial supply of VC, FEC and a third product began ahead of the previously indicated Q2 FY27 start; validation batches of the fourth product supplied from pilot scale; ramp-up expected over the next 2-3 quarters (through approximately Q1 FY 2027-2028).
• Industry demand for battery chemicals continues to exceed supply — strong ramp-up expected as orders are already in hand; the business is described as mature, self-sustained, with the third and fourth products already commercialized.
• Electrolyte realizations held at ~$10-12 vs. market prices of $30-35 — management is deliberately not riding the spot-price wave, prioritizing long-term contracts, steady profit and timely payback; some additional realization from price movement is expected but not at $30-35 — an "early teens" pricing scenario (period unspecified).
• South Korea semiconductor plant inaugurated ahead of schedule in Q1 FY 2026-2027 — currently in customer qualification; management is not committing to any revenue from the facility in FY 2026-2027, with initial revenue expected only from FY 2027-2028 onward and not "huge revenue or profitability" initially.
• Electronic grade chemicals capex of Rs.1,000 million planned in H2 FY27 — part of ~Rs.3,000 million FY 2026-2027 total capex guidance (excludes R&D capex and land acquisition); capex completion in ~1.5 years with production start expected by H1 FY 2028-2029; management corrected the analyst's 2x asset turnover assumption to at least 3x.
• Semiconductor business is export-focused for now — capacity is planned for the Korean ecosystem and outside-Korea geographies such as Japan and Taiwan; management said the Indian semiconductor ecosystem is "yet not that matured" and no Indian demand exists today as fabs have not started.

Pharma Leads, Specialty Muted, Utilization Still Low

• Advanced pharmaceutical intermediates revenue of Rs.4,020 million, up 53.1% YoY — the core pharma business grew more than 25% YoY on new-product ramp-up and top-product strength; pharma intermediates vertical revenue was Rs.695 crore in H1 FY 2026-2027 (per slide 6).
• Specialty chemicals revenue of Rs.349 million, down 20% YoY — due to phasing out of old commodity products and a temporary pause in BFC shipments caused by the Q2 FY 2026-2027 ownership change of the US customer; supplies have resumed and management is on target for BFC growth in FY 2026-2027.
• Steady-state quarterly specialty chemicals revenue expected at H1 FY27 levels — with overall growth versus FY 2025-2026 as battery chemicals ramps up; management declined to split the Rs.349 million between legacy and battery chemicals.
• CDMO Unit 2 at Ankleshwar at 30% utilization in Q2 FY 2026-2027 — against cumulative investment of Rs.330 crore; utilization should not exceed ~40% by end of FY 2026-2027 and is expected to be largely filled up (peak utilization) by FY 2027-2028; beyond FY 2026-2027, utilization is difficult to predict (no FY30 guidance given).
• Daro facility utilization at only 30% as of Q2 FY 2026-2027 — leaving some room, but management declined to disclose whether existing capacity can support doubling supply or whether additional capex would be needed.
• Legacy Paraben and MS products being scaled down — Paraben scale-down may take around 1-1.5 years, while MS may take beyond 1.5 years (timelines given on the Q2 FY 2026-2027 call), as existing customers need time to develop alternative vendors.

Management Declines Comment on Indication-Expansion Upside

• Bayer's trial showed reduced risk of metastasis or death by 58% — in high-risk localized prostate cancer; Union AMC's Parth Dalia asked about the volume opportunity if the darolutamide indication expansion is approved over the next 2-3 years.
• Acutaas is an intermediate supplier for the darolutamide API — Abhishek Patel clarified the trial/indication pertains to the formulation market and, being "at the bottom of the pyramid," the company cannot comment on the innovator's programs.
• Management sees good traction in the product over the next three years (FY 2027-2028 to FY 2029-2030) — it tracks offtake from its customer and should be a beneficiary of whatever the customer gains; this underpins the guidance it has given.
• On whether the trial upgrades the innovator's formulation sales, both Abhishek Patel and CFO Bhavin Shah declined to comment — stating they are "not very well placed" to assess formulation-market volumes; no new volume guidance or capacity commitment was offered.
• CDMO project pipeline has grown from ~4 to 7-8 projects — per analyst Pratik Dharamshi's count as of Q2 FY 2026-2027; management declined therapy-area and per-molecule detail but flagged some "very exciting" projects with better revenue possibility.

Diversification Vision, Capital Discipline and Flagged Risks

• Five-year aim: a multi-sector chemical company — management wants Acutaas known for supplying battery, semiconductor and electronics sectors rather than as a pharma-chemical company; Naresh Patel called the last decade the foundation/seeding phase and expects the coming decade to be the most important, delivering the fruits of that seeding.
• Generic portfolio visibility to 2045 — the research department has developed multiple molecules with patent expiry up to 2045; long-term agreements with several regulated-market customers provide visibility for the next three years.
• Capital deployment and ROE focus — Abhishek Patel said strategy deliberately avoids riding the $30-35 pricing wave in favor of sticky customer relationships, aiming to make each business a long-term, sustainable cash-generating operation.
• Key risks flagged by Naresh Patel — geopolitical issues, supply chain, logistics, electricity and water constraints; any delay in India's semiconductor ecosystem would delay the company's implementation; and competition may limit how much of the China-free opportunity Indian chemical manufacturers can capture.
• Land acquisition for future CDMO capacity has begun — against the Rs.2,000 crore CDMO capex guidance by FY30 (FY 2029-2030), management said Ankleshwar utilization may get filled up by FY30; size and scale of the next capex round will be decided based on this.
• Validation is customer-specific — Naresh Patel clarified one large customer's approval does not transfer to others and the process is "robust, long-term, time-consuming," though validated high-end chemical manufacturing capability gives the company an advantage versus competitors for future Indian customers.